semaglutide

Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market
Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market
Fierce Pharma
Novo Nordisk
obesity
drug launches
Wegovy
semaglutide
Flag link:
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Fierce Pharma
Novo Nordisk
semaglutide
obesity
FDA
Flag link:
Go or no go? Aducanumab’s day of reckoning
Go or no go? Aducanumab’s day of reckoning
EP Vantage
Biogen
FDA
aducanumab
Ascendis Pharma
Novo Nordisk
TransCon hGH
semaglutide
Flag link:
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Endpoints
Novo Nordisk
diabetes
obesity
semaglutide
oral semaglutide
clinical trials
Flag link:
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
Benzinga
Novo Nordisk
FDA
diabetes
semaglutide
RTF letters
Flag link:
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Fierce Biotech
Eli Lilly
Novo Nordisk
tirzepatide
semaglutide
type 2 diabetes
clinical trials
Flag link:
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Yahoo/Global Newswire
Novo Nordisk
FDA
Ozempic
type 2 diabetes
semaglutide
Flag link:
Gilead and Novo plot next steps after trial data from NASH combo
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
Flag link:
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Flag link:
Novo adds weight to its obesity goals
Novo adds weight to its obesity goals
EP Vantage
Novo Nordisk
semaglutide
obesity
Flag link:
Novo launches type 2 diabetes pill in UK after NICE waives review
Novo launches type 2 diabetes pill in UK after NICE waives review
Pharmaforum
Novo Nordisk
UK
type 2 diabetes
diabetes
Rybelsus
semaglutide
NICE
Flag link:
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Fierce Biotech
Novo Nordisk
obesity
semaglutide
Flag link:
Novo's diabetes drug also appears to work in NASH
Novo's diabetes drug also appears to work in NASH
BioPharma Dive
Novo Nordisk
NASH
semaglutide
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk seeks FDA nod for oral diabetes pill
Drug Delivery Business News
Novo Nordisk
FDA
semaglutide
diabetes
Flag link:
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Fierce Pharma
Novo Nordisk
diabetes
Teva Pharmaceutical
Victoza
semaglutide
Flag link:
Novo bets on swift FDA review for oral diabetes drug semaglutide
Novo bets on swift FDA review for oral diabetes drug semaglutide
Endpoints
Novo Nordisk
earnings
semaglutide
FDA
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:

Pages